



Page 1 of 2

Form PTO 1449							
ATTY DOCKET NO. 88-98		SERIAL NO. 09/435,403		FILING DATE November 5, 1999			
APPLICANT Lollar				GROUP 1646 1653			

**U.S. PATENT DOCUMENTS**

Exmr Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
HS	1	5,859,204	1/12/99	Lollar	530	383	

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclass	Translation Yes/No

**OTHER PRIOR ART (including Author, Title, Date, Pertinent Pages, etc.)**

HS	2	Aledort, L., "Inhibitors in hemophilia Patients: Current Status and Management"; (1994) <i>Am. J. Hematol.</i> (Review) 47:208-217.
VS	3	Eaton, D.L. et al., "Construction and Characterization of an Active Factor VIII Variant Lacking the Central One-Third of the Molecule"; (1986) <i>Biochemistry</i> 25:8343-8347.
VS	4	Fulcher, C.A. et al., "Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments"; (1985) <i>Proc. Natl. Acad. Sci. USA</i> 82:7728-7732.
VS	5.	Healey, J.F. et al., "Residues 484-508 Contain a Major Determinant of the Inhibitory Epitope in the A2 Domain of Human Factor VIII"; (1995) <i>J. Biol. Chem.</i> 270:14505-14509.
VS	6	Healey, J.F. et al., "Residues Glu2181-Val2243 Contain a Major Determinant of the Inhibitory Epitope in the C2 Domain of Human Factor VIII"; (1998) <i>Blood</i> 92:3701-3709.
VS	7	Kasper, C.K. et al., "A More Uniform Measurement of Factor VIII Inhibitors"; (1975) <i>Thromb. Diath. Haemorrh.</i> 34:869-872.
VS	8	Lubin, I.M. et al., "Elimination of a Major Inhibitor Epitope in Factor VIII"; (1994) <i>J. Biol. Chem.</i> 269:8639-8641.
VS	9.	Lubin, I.M. et al., "Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis"; (1997) <i>J. Biol. Chem.</i> 272:30191-30195.

Tony Lollar

1-4-00



Page 2 of 2

APR 01 2000

TECH CENTER  
1600/2900

Form PTO 1449

ATTY DOCKET NO. 88-98	SERIAL NO. 09/435,403	FILING DATE November 5, 1999
APPLICANT Lollar		GROUP 1646

HS	10	Lusher, J.M. et al., "Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A"; (1993) <i>N. Engl. J. Med.</i> <b>328</b> :453-459.
HS	11	McMillan, C.M. et al., "The Natural History of Factor VIII:C Inhibitors in Patients With Hemophilia A: A National Cooperative Study.II. Observations on the Initial Development of Factor VIII:C Inhibitors"; (1988) <i>Blood</i> <b>71</b> :344-348.
HS	12	Scandella, D. et al., "Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in <i>Escherichia coli</i> "; (1988) <i>Proc. Natl. Acad. Sci. USA</i> <b>85</b> :6152-6156.
HS	13	Scandella, D. et al., "A Recombinant Factor VIII A2 Domain Polypeptide Quantitatively Neutralizes Human Inhibitor Antibodies That Bind to A2"; (1993) <i>Blood</i> <b>82</b> :1767-1775.
HS	14	Vehar, G.A. et al., "Structure of human factor VIII"; (1984) <i>Nature</i> <b>312</b> :337-3.
HS	15	Wyatt, R. et al., "The antigenic structure of the HIV gp120 envelope glycoprotein"; (1998) <i>Nature</i> <b>393</b> :705-711.

EXAMINER		DATE CONSIDERED	1-4-00
----------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

12/20/89